Study on Effects of preconditioning of Remifentanil on Vascular Endothelial Cells in Patients with Cardiopulmonary Bypass

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005829

Enrollment

Unknown

Registered

2015-01-15

Start date

2015-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disease of mitral valve

Interventions

remifentanil preconditioning group and control group:remifentanil preconditioning

control group:Physiological saline preconditioning

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 37-62 years old; 2. American Socity of Anesthesiologists physician status (ASA)II to III; 3. all patients were scheduled for mitral valve replacement performed via conventional cardiopulmonary bypass.

Exclusion criteria

Exclusion criteria: Patients with suffering from cancer, liver and kidney dysfunction, taking immunosuppressants, cytotoxic drugs, hormone replacement therapy were excluded from this study. Patients usingaspirin, warfarin and heparin before surgery were also excluded.

Design outcomes

Primary

Measure	Time frame
circulating endothelial cell;	—

Secondary

Measure	Time frame
thrombomodulin;NO;endothelial function;	—

Countries

China

Contacts

Public ContactChun Chen

664768517@qq.com+86 13607203416

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026